Menstrual Cycle on Injection Pain of Rocuronium (MENS)

Aydin Adnan Menderes University

Status: Completed

Conditions: Pain, Menstrual

Treatments: Drug: Rocuronium 0,6mg/kg

Study type: Interventional

Funder types: Other

Identifiers

NCT02539706

sinan

Details and patient eligibility

About

This study evaluates the effects of rocuronium injection pain to menstrual cycle phases.Half of participants will receive follicular phase, while the other half will receive luteal phase.

Full description

Menstrual period includes a spectrum of emotional and somatic symptoms observed in luteal phase of menstrual cycle, which are disappeared after menstruation.

During menstrual cycle, fluctuation in sexual hormones results in attitude change and alteration in pain perception.

Different studies reported some interactions between sex hormones and central nervous system, which might be linked to activity of serotonin and beta-endorphin in the brain.

Pain perception differs during menstrual cycle.

It has been recommended that estrogens might have an influence on somatic sensory process.

Some studies reported a significant effect of pain sensitivity with higher levels of progesterone and some other studies reported similar patterns for pain perception.

There are reports of more complaint of pain in luteal phase of menstruation, which is suggested as the reason for functional changes in women during menstrual cycle.

Enrollment: 100 patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• American Society of Anesthesiology Classification (ASA) I-II
• 18-45 years
• Regular menstrual cycle

Exclusion criteria

• Irregular menstrual cycles
• Patients receiving hormones or drugs affecting the ovulatory cycle
• Amenorrhea
• Pregnancy
• Climacteric patients

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups

Follıcular group

Experimental group

Description:

patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.

Treatment:

Drug: Rocuronium 0,6mg/kg

Drug: Rocuronium 0,6mg/kg

Luteal group

Active Comparator group

Description:

patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.

Treatment:

Drug: Rocuronium 0,6mg/kg

Drug: Rocuronium 0,6mg/kg